0001819790-24-000047.txt : 20240319
0001819790-24-000047.hdr.sgml : 20240319
20240319190833
ACCESSION NUMBER: 0001819790-24-000047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240319
DATE AS OF CHANGE: 20240319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mottiwala Aziz
CENTRAL INDEX KEY: 0001788542
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 24765696
MAIL ADDRESS:
STREET 1: 233 WILSHIRE BOULEVARD
STREET 2: SUITE 280
CITY: SANTA MONICA
STATE: CA
ZIP: 90401
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wk-form4_1710889691.xml
FORM 4
X0508
4
2024-03-15
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001788542
Mottiwala Aziz
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
Chief Commercial Officer
0
Common Stock
2024-03-15
4
M
0
12938
A
58841
D
Common Stock
2024-03-18
4
S
0
4766
30.60
D
54075
D
Restricted Stock Units
2024-03-15
4
M
0
4790
0
D
Common Stock
4790
9580
D
Restricted Stock Units
2024-03-15
4
M
0
8148
0
D
Common Stock
8148
24444
D
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
Includes 97 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2023.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
/s/ Jeffrey Farrow, Attorney-in-Fact
2024-03-19